What medication can lead to an increased risk of developing dyskinesias when given in combination with levodopa/carbidopa?

Amantadine is an antiviral medication that also has properties that can help manage symptoms of Parkinson's disease. When used in conjunction with levodopa/carbidopa, it is known to have a synergistic effect that can enhance the dopaminergic activity, potentially leading to an increased risk of developing dyskinesias. Dyskinesias are involuntary, erratic movements that can be a side effect of long-term levodopa therapy, and adding amantadine can exacerbate this issue.

In Parkinson's treatment, while levodopa remains the cornerstone, various adjunct medications are often prescribed to enhance its efficacy or manage side effects. Amantadine’s role as an adjunctive treatment can unfortunately amplify the likelihood of dyskinetic movements due to its dopaminergic effects. It is essential to monitor patients carefully for these movements when combining these medications.

Other medications listed do not share the same level of interaction in increasing the risk of dyskinesias when combined with levodopa/carbidopa, making amantadine the focus in this scenario.